| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(79)92440-1 |
| P8608 | Fatcat ID | release_f4indasjx5amnlht4jjdki3zxm |
| P953 | full work available at URL | https://api.elsevier.com/content/article/PII:S0140673679924401?httpAccept=text/plain |
| https://api.elsevier.com/content/article/PII:S0140673679924401?httpAccept=text/xml | ||
| P698 | PubMed publication ID | 91781 |
| P2093 | author name string | D. J. White | |
| R. G. Henderson | |||
| K. Rolles | |||
| R. Y. Calne | |||
| D. B. Evans | |||
| P. McMaster | |||
| S. Aziz | |||
| P. Lewis | |||
| G. N. Craddock | |||
| D. C. Dunn | |||
| S. Thiru | |||
| P2860 | cites work | Cyclosporin A in patients receiving renal allografts from cadaver donors | Q34347891 |
| Extensive prolongation of rabbit kidney allograft survival after short-term cyclosporin-A treatment | Q39492210 | ||
| Prolonged survival of pig orthotopic heart grafts treated with cyclosporin A. | Q39492216 | ||
| Idiopathic cardiomyopathy, age, and suppressor-cell dysfunction as risk determinants of lymphoma after cardiac transplantation | Q39516752 | ||
| Cyclosporin A for the treatment of graft-versus-host disease in man | Q39521114 | ||
| Prolongation of kidney survival during and after cyclosporin A therapy | Q41027134 | ||
| Selective effects of cyclosporin A on colony-forming lymphoid and myeloid cells in man | Q80983586 | ||
| P433 | issue | 8151 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pancreas | Q9618 |
| cyclosporine | Q367700 | ||
| immunosuppression | Q1455316 | ||
| immunologic graft enhancement | Q72389588 | ||
| P304 | page(s) | 1033-1036 | |
| P577 | publication date | 1979-11-01 | |
| 1979-11-17 | |||
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers | |
| P478 | volume | 2 |
| Q48288606 | "It can't be done". |
| Q47329019 | 1000 liver transplantations at the Department of General, Transplant and Liver Surgery, Medical University of Warsaw--analysis of indications and results |
| Q43633114 | 1954. |
| Q42408980 | 99mTc-DTPA and 131I-hippuran findings in liver transplant recipients treated with cyclosporin A. |
| Q70946075 | A Radioimmunoassay to Measure Cyclosporin a in Plasma and Serum Samples |
| Q70277015 | A Randomized Clinical Trial of Cyclosporine in Cadaveric Renal Transplantation |
| Q43782651 | A histomorphological investigation of the effect of cyclosporin on trabecular bone of the rat mandibular condyle |
| Q47614976 | A historic perspective of liver surgery for tumors at the end of the millennium |
| Q42535946 | A modern Cosmas and Damian: Sir Roy Calne and Thomas Starzl receive the 2012 Lasker~Debakey Clinical Medical Research Award |
| Q41177624 | A new microemulsion formulation of cyclosporin: pharmacokinetic and clinical features |
| Q39629956 | A pediatric perspective on liver transplantation. |
| Q46702756 | A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. |
| Q33567138 | Acquired immunologic tolerance: with particular reference to transplantation |
| Q40186474 | Acute cellular rejection or Cyclosporine A nephrotoxicity? A review of transplant renal biopsies |
| Q40778807 | Advances in human leukocyte antigens and transplantation |
| Q38544529 | Advances in pharmacotherapy to treat kidney transplant rejection |
| Q69864969 | Alternate day cyclosporin and azathioprine plus steroids |
| Q54199475 | Ameliorated effect of L-arginine supplementation on gingival morphology in cyclosporin-treated rats. |
| Q46132760 | Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience |
| Q34201191 | Animal research in liver transplantation with special reference to the dog. |
| Q35544018 | Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status. |
| Q37691180 | Antibody immunosuppressive therapy in solid-organ transplant: Part I. |
| Q40184313 | Antibody response after influenza immunization in renal transplant patients receiving cyclosporin A or azathioprine |
| Q34201121 | Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation |
| Q70930242 | Antischistosomal effects of cyclosporin A |
| Q53482976 | Arteriosclerosis in zero-time biopsy is a risk factor for tacrolimus-induced chronic nephrotoxicity. |
| Q72593341 | Association between cyclosporin neurotoxicity and hypomagnesaemia |
| Q35160259 | Back to the future. |
| Q36826185 | Beyond five years: long-term follow-up in pediatric liver transplantation |
| Q44646674 | Bilateral iris tumors in an immunosuppressed child |
| Q41109791 | Biliary Excretion of Cyclosporine in Liver Transplant Patients |
| Q35017865 | Biological aspects of Epstein-Barr virus (EBV)-infected lymphocytes in chronic active EBV infection and associated malignancies |
| Q37455947 | Blockade of protein phosphatase 2B activity in the amygdala increases anxiety- and depression-like behaviors in mice |
| Q48656763 | Blood and tissue distribution of cyclosporin A after a single oral dose in the rat. |
| Q46403134 | Blood pressure elevation in long-term survivors of pediatric liver transplantation |
| Q34781790 | CRITICAL CARE MEDICINE AND LIVER TRANSPLANTATION. |
| Q41105613 | Cadaveric Renal Transplantation With Cyclosporin-A and Steroids. |
| Q34942321 | Cadaveric Renal Transplantation in Diabetics in the 1980's: with Special Reference to Cyclosporine |
| Q37310997 | Cadaveric renal transplantation under cyclosporine-steroid therapy |
| Q33680438 | Calcineurin downregulation in the amygdala is sufficient to induce anxiety-like and depression-like behaviors in C57BL/6J male mice |
| Q35702432 | Cancer after transplantation |
| Q41886382 | Cancer in organ transplant recipients: part of an induced immune deficiency syndrome. |
| Q34187607 | Canine liver transplantation under Nva2-cyclosporine versus cyclosporine |
| Q35711246 | Cardiac transplant experience with cyclosporine |
| Q50932866 | Cardiac transplantation with cyclosporin A and prednisone. |
| Q34434481 | Chimerism after Whole Organ Transplant |
| Q34201706 | Chimerism after organ transplantation |
| Q35866668 | Chimerism and tolerance in transplantation |
| Q43442357 | Chlamydial ophthalmia neonatorum in Central Africa |
| Q54103458 | Clinical analysis of hyperkalemic renal tubular acidosis caused by calcineurin inhibitors in solid organ transplant recipients. |
| Q35948242 | Clinical experience in 200 renal transplants at Catholic Medical Center |
| Q45100343 | Combined 'en bloc' liver and pancreas transplantation in patients with liver disease and type 1 diabetes mellitus |
| Q45348121 | Comparative efficacy of Belzer or Euro-Collins solutions for pancreatic preservation during cold ischemic storage in rats |
| Q54258058 | Comparison of Azathioprine-Antilymphocyte Globulin versus Cyclosporine in Renal Transplantation |
| Q39738014 | Complications of cyclosporin therapy |
| Q36612344 | Composite tissue allotransplantation of the hand and face: a new frontier in transplant and reconstructive surgery. |
| Q42355459 | Cone fusion confusion in photoreceptor transplantation |
| Q42670037 | Controversial aspects of the current liver donor allocation system for liver transplantation |
| Q38241710 | Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients |
| Q42152163 | Convulsions associated with cyclosporin A in renal transplant recipients |
| Q40150267 | Corneal allograft rejection. The role of the major histocompatibility complex |
| Q70804117 | Cosmas and Damian in the 20th Century? |
| Q92134153 | Coupled feedback regulation of nuclear factor of activated T-cells (NFAT) modulates activation-induced cell death of T cells |
| Q63987408 | Creating molecules that modulate immune responses |
| Q36649380 | Critical care perspective on immunotherapy in lung transplantation |
| Q34207236 | Current Status of Hepatic Transplantation |
| Q38002369 | Current concepts in pediatric liver transplantation |
| Q37097910 | Current concepts in transplant surgery: liver transplantation today |
| Q34866559 | Current status of small bowel and multivisceral transplantation |
| Q37164604 | Cyclosporin A and steroid therapy in sixty-six cadaver kidney recipients |
| Q72127079 | Cyclosporin A and the media |
| Q33477264 | Cyclosporin A associated nephrotoxicity in the first 100 days after allogeneic bone marrow transplantation: three distinct syndromes |
| Q69897143 | Cyclosporin A effective therapy for fifty-two cadaver kidney recipients |
| Q72482806 | Cyclosporin A immunosuppression and Epstein-Barr antibody |
| Q44774139 | Cyclosporin A immunosuppression, Epstein-Barr antibody, and lymphoma |
| Q34778331 | Cyclosporin A in cadaveric organ transplantation |
| Q36660164 | Cyclosporin A in clinical organ grafting. First Northern Ireland Kidney Research Fund lecture. |
| Q72500702 | Cyclosporin A in oliguric renal transplant recipients |
| Q50563197 | Cyclosporin A in paediatric kidney transplantation. |
| Q40606170 | Cyclosporin A induces proliferation in human gingival fibroblasts via induction of transforming growth factor-beta1. |
| Q37564002 | Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription |
| Q45838208 | Cyclosporin A inhibits induction but not production of gamma interferon induced by Epstein-Barr virus |
| Q45802718 | Cyclosporin A promotes spontaneous outgrowth in vitro of Epstein–Barr virus-induced B-cell lines |
| Q72419264 | Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation |
| Q72441192 | Cyclosporin A, transplantation, and lymphoma |
| Q72114373 | Cyclosporin A-immunobiological aspects |
| Q43651087 | Cyclosporin A-induced gingival overgrowth is unrelated to allograft function in renal transplant recipients |
| Q64925890 | Cyclosporin A: Effects on the mouse thymus |
| Q40615260 | Cyclosporin A: a new advance in transplantation. |
| Q70436213 | Cyclosporin A: correlation between HPLC and RIA serum levels |
| Q70302607 | Cyclosporin a used alone or in combination with low-dose steroids in cadaveric renal transplantation |
| Q36998081 | Cyclosporin a. Inhibition of experimental autoimmune uveitis in Lewis rats |
| Q70302612 | Cyclosporin a: Pharmacologic activity on the immune system and effects in clinical organ transplantation |
| Q36745451 | Cyclosporin and the gingival tissues |
| Q40918376 | Cyclosporin clinical pharmacokinetics |
| Q69895029 | Cyclosporin conversion versus conventional immunosuppression: long-term follow-up and histological evaluation |
| Q72556296 | Cyclosporin-A deposits in renal allografts |
| Q43701113 | Cyclosporin-induced gingival overgrowth at the newly formed edentulous ridge in rats: a morphological and histometric evaluation |
| Q46651213 | Cyclosporin-induced gingival overgrowth: a clinical-epidemiological evaluation of 121 Italian renal transplant recipients |
| Q39417386 | Cyclosporine A disposition, hepatic and renal tolerance in Wistar rat. |
| Q89985602 | Cyclosporine A inhibits MRTF-SRF signaling through Na+/K+ ATPase inhibition and actin remodeling |
| Q69914465 | Cyclosporine and partial liver allotransplants in a simplified rat model |
| Q35710789 | Cyclosporine as a milestone in immunosuppression |
| Q39699974 | Cyclosporine conversion |
| Q39828496 | Cyclosporine in cardiac transplantation |
| Q35711056 | Cyclosporine in pediatric kidney transplantation |
| Q46762402 | Cyclosporine in the treatment of steroid resistant rejection episodes in living donor kidney transplants |
| Q48908437 | Cyclosporine-A increases locomotor activity in rats with 6-hydroxydopamine-induced hemiparkinsonism: relevance to neural transplantation |
| Q70318562 | Cyclosporine. Kidney transplantation |
| Q35710924 | Cyclosporine: 20 years of experience at the University of Munich. |
| Q70309967 | Cyclosporine: Five Years' Experience in Cadaveric Renal Transplantation |
| Q40176613 | Cyclosporine: a powerful addition to the immunosuppressive armamentarium |
| Q35675934 | Cyclosporine: a review |
| Q38204714 | Cyclosporine: a review and its specific use in liver transplantation |
| Q40200051 | Cyclosporine: immunology, toxicity and pharmacology in experimental animals |
| Q41352078 | Cyclosporine: progress, problems, and perspectives. |
| Q39689835 | Cyclosporine: structure, pharmacokinetics, and therapeutic drug monitoring |
| Q40327589 | Depressed immunity and the development of cancer. |
| Q68881045 | Diagnosis and treatment of infection in cardiac transplant patients |
| Q77900356 | Differential Th1 and Th2 cell regulation of murine cardiac allograft acceptance by blocking cell adhesion of ICAM-1/LFA-1 and VCAM-1/VLA-4 |
| Q40489665 | Discovery of FK‐506 and Update |
| Q43598374 | Does nifedipine aggravate cyclosporin--induced gingival overgrowth? An experiment in rats |
| Q42217408 | Early and late forms of cyclosporine nephrotoxicity: studies in cardiac transplant recipients |
| Q39250118 | Early clinical xenotransplantation experiences-An interview with Thomas E. Starzl, MD, PhD. |
| Q36139770 | Early results of cardiac transplantation at the Texas Heart Institute |
| Q59059040 | Effect of cyclosporin A on T-dependent and T-independent immunoglobulin synthesis in vitro |
| Q46839064 | Effect of cyclosporin A on the expression of inducible nitric oxide synthase in the gingiva of rats |
| Q43468003 | Effect of cyclosporin a on the production of interferon by human peripheral blood leukocytes in vitro |
| Q80381364 | Effect of orange and tangerine juice on cyclosporine levels in renal transplant recipients |
| Q42169467 | Effects of and predictors for tacrolimus rescue therapy among renal transplant patients under cyclosporine-based immunosuppression |
| Q72440691 | Effects of cyclosporin A on suppressor and inducer T lymphocytes in primary biliary cirrhosis |
| Q78165144 | Effects of cyclosporin A on the mandibular condylar cartilage in rats |
| Q80275641 | Effects of cyclosporine and tacrolimus on the oxidative stress in cultured mesangial cells |
| Q36164160 | Efficacy and Safety of Monotherapy With Mycophenolate Mofetil in Liver Transplantation Patients With Nephrotoxicity |
| Q41341000 | Efficacy and safety of a reduced calcineurin inhibitor dose combined with mycophenolate mofetil in liver transplant patients with chronic renal dysfunction |
| Q38786418 | Emerging drugs for prevention of T-cell mediated rejection in liver and kidney transplantation |
| Q36758582 | Emerging drugs in lung transplantation |
| Q45806697 | Epstein Barr virus nuclear antigen positive lymphoma after cyclosporin A treatment in patient with renal allograft |
| Q40834086 | Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Clinical, pathologic, and virologic findings and implications for therapy. |
| Q36633160 | Epstein-Barr virus and human diseases: recent advances in diagnosis |
| Q34415885 | Epstein-Barr virus in patients with immunodeficiency disorders |
| Q41204114 | Epstein-Barr virus in tumours |
| Q39494552 | Epstein-Barr virus infection and immunoregulation in man. |
| Q35160206 | Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection |
| Q36439929 | Epstein-Barr virus-associated lymphoproliferative disorders in immunocompromised individuals. |
| Q39510505 | Epstein-Barr virus-associated malignancies |
| Q41874828 | Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites |
| Q35711203 | Evolution of immunosuppression in liver transplantation: contribution of cyclosporine |
| Q34275840 | Evolution of liver transplantation |
| Q79819422 | Experience with cyclosporine |
| Q70386814 | Experience with cyclosporine and steroids in clinical renal transplantation |
| Q35711084 | Experience with cyclosporine in pediatric renal transplantation |
| Q46935417 | Expression of cell-surface heparan sulfate proteoglycans in human cyclosporin-induced gingival overgrowth. |
| Q44247073 | Expression of matrix metalloproteinases in cyclosporin-treated gingival fibroblasts is regulated by transforming growth factor (TGF)-beta1 autocrine stimulation. |
| Q34252199 | FK 506 for liver, kidney, and pancreas transplantation |
| Q33993337 | Factors in the Development of Liver Transplantation. |
| Q42357847 | Fiftieth anniversary of the first heart transplant: The progress of American medical research, the ethical dilemmas, and Christiaan Barnard. |
| Q33884015 | Fifty landmark discoveries in gastroenterology during the past 50 years. A brief history of modern gastroenterology at the millennium: Part I. Gastrointestinal procedures and upper gastrointestinal disorders |
| Q26822887 | From immunosuppression to tolerance |
| Q44770829 | Gene expression of extracellular matrix proteoglycans in human cyclosporin-induced gingival overgrowth |
| Q91899623 | Gene therapy in surgery: Part II: Application to septic shock and to organ transplantation |
| Q34554254 | Generalised epileptic fits in renal transplant recipients given cyclosporin A. |
| Q40325057 | Glomerular Diseases and Renal Transplantation: Pathogenic Pathways and Evolution of Therapeutic Interventions |
| Q41787691 | HLA matching effect in liver transplantation |
| Q37663649 | Healthcare costs in renal transplant recipients using branded versus generic ciclosporin |
| Q42084523 | Hepatic and renal function in rats receiving immunotherapeutic doses of cyclosporin A |
| Q40091471 | Hepatic transplantation: the state of play |
| Q27486176 | Hepatology |
| Q70976523 | High pressure liquid chromatographic determination of cyclosporin A in plasma |
| Q34131645 | Histiocytic Lymphoma in Renal Transplant Patients Receiving Cyclosporine |
| Q36933185 | Historical overview of transplantation |
| Q40136744 | Historical perspective of living donor liver transplantation |
| Q38373018 | Historical perspectives in kidney transplantation: an updated review |
| Q24596303 | History of clinical transplantation |
| Q34824972 | Hypertensinogenic mechanism of the calcineurin inhibitors |
| Q34275902 | Identifying the patient at risk for post-transplant lymphoproliferative disorder |
| Q40317133 | Immune suppression with cyclosporin A-optimism and caution |
| Q45806405 | Immunity to Epstein-Barr virus in cyclosporin A-treated renal allograft recipients |
| Q58630830 | Immunohistochemical Analysis of Lymphocyte Subpopulations in Cyclosporin A-Induced Gingival Overgrowth |
| Q72458883 | Immunological and pharmacological monitoring in the clinical use of cyclosporin A |
| Q34277866 | Immunological and regenerative aspects of hepatic mast cells in liver allograft rejection and tolerance |
| Q44548792 | Immunological risk factors are solely responsible for primary non-function of renal allografts. |
| Q38044761 | Immunomodulating options for liver transplant patients |
| Q38040507 | Immunomodulating therapy in liver transplantation: principles and practice |
| Q34286455 | Immunosuppression and other nonsurgical factors in the improved results of liver transplantation |
| Q71652511 | Immunosuppression in Liver Transplantation |
| Q52101561 | Immunosuppression with cyclosporin A in allogeneic bone marrow transplantation for severe aplastic anaemia: preliminary studies. |
| Q93667577 | Immunosuppressive activity and toxicity of cyclosporin A in rats pretreated with high dose cyclophosphamide |
| Q35156223 | Immunosuppressive drugs in renal transplantation. A review of the regimens |
| Q36652040 | Immunosuppressive standards in simultaneous kidney-pancreas transplantation |
| Q74597203 | Immunosuppressive therapy |
| Q35710933 | Impact of cyclosporine on the development of immunosuppressive therapy. |
| Q42163344 | Impact of late conversion from C0 to C2 monitoring of microemulsified cyclosporine in pediatric living donor liver transplant recipients |
| Q68890891 | Improved outcome of renal transplantation with cyclosporine compared with azathioprine--experience in 33 recipients followed for over one year |
| Q39791190 | Improved patient and graft survival using cyclosporin A in cadaver renal transplantation |
| Q70540782 | In vitro characteristics on human lymphocyte functions of a new immunomodulatory agent, a cyclic peptide, cyclomunine |
| Q34529385 | In vitro effect of cyclosporin A on immunoglobulin production and concanavalin A induced suppression in primary biliary cirrhosis |
| Q46101249 | Increased septic complications with three-drug sequential immunosuppression for cadaver renal transplants |
| Q44186332 | Induction therapy including antithymocyte globulin induces marked alterations in T lymphocyte subpopulations after liver transplantation: results of a long-term study. |
| Q40856911 | Infectious disease complications of renal transplantation |
| Q51161846 | Influence of conversion from calcineurin inhibitors to everolimus on fibrosis, inflammation, tubular damage and vascular function in renal transplant patients. |
| Q74059983 | Influences of immunosuppressive agents, FK506 and cyclosporin on systemic Candida albicans infection in mice |
| Q40821262 | Inhibition by nifedipine of adherence- and activated macrophage-induced death of human gingival fibroblasts |
| Q44847442 | Inhibition of cyclosporin A-induced gingival overgrowth by azithromycin through phagocytosis: an in vivo and in vitro study. |
| Q44793592 | Inhibition of herpes simplex virus production in vitro by Cyclosporin A |
| Q72789688 | Inhibition of the production of a soluble helper mediator by cyclosporin A results in the failure to generate alloreactive cytolytic cells in mixed-lymphocyte culture |
| Q39755522 | Intensive care aspects of organ transplantation in children |
| Q38329048 | Intestine and multivisceral transplantation: current status and future directions. |
| Q34972386 | Islet and stem cell encapsulation for clinical transplantation |
| Q51006250 | Islet/pancreas transplantation: challenges for pediatrics. |
| Q72535472 | Ketoconazole, cyclosporin metabolism, and renal transplantation |
| Q44827574 | Late experimental amebic liver abscess in hamster is inhibited by cyclosporine and N-acetylcysteine |
| Q37363431 | Late follow-up after thoracic duct drainage in cadaveric renal transplantation. |
| Q44812476 | Learning and new discovery with cyclosporine in the Cambridge-King's Programme: a personal view |
| Q24541751 | Lessons learned from more than 1,000 pancreas transplants at a single institution |
| Q64106846 | Lessons to Learn From Low-Dose Cyclosporin-A: A New Approach for Unexpected Clinical Applications |
| Q51136799 | Life quality of patients undergoing liver transplantation. |
| Q34974720 | Liver Transplantation in the World: Present Conditions of Liver Transplantation from Cadaver Donors in USA |
| Q34561587 | Liver and kidney transplantation in children receiving cyclosporin A and steroids |
| Q72421238 | Liver disease |
| Q35109007 | Liver failure, transplantation, and critical care |
| Q34359990 | Liver immunology |
| Q64116391 | Liver preservation prior to transplantation: Past, present, and future |
| Q93558344 | Liver transplantation |
| Q40966829 | Liver transplantation and its long-term management in children |
| Q34170394 | Liver transplantation at the millennium. Past, present, and future |
| Q34299465 | Liver transplantation for biliary atresia |
| Q36339458 | Liver transplantation for hepatitis C virus related liver disease |
| Q34248802 | Liver transplantation for primary biliary cirrhosis |
| Q77325632 | Liver transplantation in Brazil |
| Q38298491 | Liver transplantation in Turkey: historical review and future perspectives |
| Q36308585 | Liver transplantation in children: part 1--peri-operative issues |
| Q34275290 | Liver transplantation in the ciclosporin era. |
| Q24645567 | Liver transplantation with use of cyclosporin a and prednisone |
| Q36340199 | Liver transplantation(). |
| Q33752966 | Liver transplantation, 1980, with particular reference to cyclosporin-A. |
| Q34177197 | Liver transplantation: an unfinished product |
| Q34101719 | Liver transplantation: current concepts |
| Q33594885 | Liver transplantation: fifty years of experience |
| Q26826902 | Liver transplantation: history, outcomes and perspectives |
| Q44195675 | Liver transplantation: past, present and future |
| Q36063337 | Living donor liver transplantation: Eastern experiences |
| Q62617628 | Long-Term Survival After Liver Transplantation in 4,000 Consecutive Patients at a Single Center |
| Q45806627 | Long-term T-cell-mediated immunity to Epstein-Barr virus in renal-allograft recipients receiving cyclosporin A |
| Q68797954 | Long-term complications of renal transplantation |
| Q34396550 | Long-term results of cyclosporine-steroid therapy in 131 non-matched cadaveric renal transplants |
| Q34764753 | Long-term survival after cadaveric renal transplantation |
| Q34248652 | Long-term use of cyclosporine in liver recipients. Reduction of dosages in the first year to avoid nephrotoxicity |
| Q34275380 | Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group |
| Q72576061 | Lymphomas and lymphoproliferative lesions developing under cyclosporin therapy |
| Q34240290 | Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population |
| Q72418115 | Malignant lymphoma in cyclosporin A treated allograft recipients |
| Q40175023 | Mechanisms of Allograft Rejection: The Roles of Cytotoxic T-Cells and Delayed-Type Hypersensitivity |
| Q40132201 | Mechanisms of Viral Tumorigenesis |
| Q37849650 | Mesenchymal stem cells and progenitor cells in connective tissue engineering and regenerative medicine: is there a future for transplantation? |
| Q39220742 | Mitochondrial permeability transition in cardiac ischemia-reperfusion: whether cyclophilin D is a viable target for cardioprotection? |
| Q34170300 | Modern immunosuppression |
| Q45076857 | Mycophenolate mofetil monotherapy in liver transplant recipients |
| Q70191600 | Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: glomerular thromboses and tubular injury |
| Q42588161 | Nephrotoxicity of cyclosporin A in liver and kidney transplant patients |
| Q41930734 | Nephrotoxicity of cyclosporine in liver transplantation |
| Q37622487 | Novel inhibitors of the calcineurin/NFATc hub - alternatives to CsA and FK506? |
| Q36830358 | Nuclear antigens and auto/alloantibody responses: friend or foe in transplant immunology. |
| Q40464601 | One hundred thirty-two consecutive pediatric liver transplants without hospital mortality: lessons learned and outlook for the future. |
| Q44185159 | Optimising immunosuppression |
| Q35125761 | Optimizing the long-term outcome of renal transplants: opportunities created by sirolimus |
| Q70416817 | Organ transplantation with special emphasis on Cyclosporin A |
| Q34286210 | Organ transplantation--then and now |
| Q42864023 | Organ transplantation: a practical triumph and epistemologic collapse |
| Q73984050 | Orthotopic liver transplantation from non-heart-beating cadaver donors in the rat: a preliminary study |
| Q44811289 | Outcome Analysis of 71 Clinical Intestinal Transplantations |
| Q35017877 | Overview and problematic standpoints of severe chronic active Epstein-Barr virus infection syndrome |
| Q67265396 | Paediatric cadaveric renal transplantation. Initial experience with a triple therapy immunosuppressive regimen |
| Q34701213 | Pancreas and islet cell transplantation |
| Q40260748 | Pancreas and islet transplantation. II. Clinical trials |
| Q44812494 | Pancreas-kidney transplantation in Japan: impact of cyclosporine on the development of immunosuppressive therapy |
| Q34275886 | Past and future prospects of orthoptic liver transplantation |
| Q34126606 | Past, present, and future research in the field of composite tissue allotransplantation |
| Q33542760 | Patterns of malignancies following renal transplantation |
| Q41105542 | Pediatric Liver Transplantation Under Therapy With Cyclosporin-A and Steroids |
| Q40695046 | Pediatric kidney transplantation: historic hallmarks and a personal perspective |
| Q68177096 | Pediatric liver transplantation |
| Q47355275 | Pediatric liver transplantation: the Montreal experience |
| Q44776826 | Penicillamine in Wilson's disease |
| Q34286168 | Peripheral blood T lymphocytes found in renal allograft recipients treated with cyclosporine |
| Q35710811 | Pharmacology of calcineurin antagonists |
| Q91860378 | Pharmacology of mitochondrial permeability transition pore inhibitors |
| Q35122852 | Phosphorylation of Epstein-Barr virus ZEBRA protein at its casein kinase 2 sites mediates its ability to repress activation of a viral lytic cycle late gene by Rta. |
| Q44776777 | Post-transplant acute renal failure in cadaver renal recipients treated with cyclosporine |
| Q33362801 | Postoperative complications of liver transplantation: relationship with mortality |
| Q26774922 | Postreperfusion syndrome during liver transplantation |
| Q80783395 | Posttransplant lymphoproliferative disorders after liver transplantation: analysis of early and late cases in a 255 patient series |
| Q35858507 | Prevention of diabetes mellitus in the BB/W rat with Cyclosporin-A |
| Q40880337 | Prevention of transplant rejection: current treatment guidelines and future developments |
| Q44732266 | Preventive OKT3 treatment with cyclosporine (Sandimmun) for second kidney transplantation |
| Q69521617 | Primary Hodgkin's lymphoma: an unusual cause of graft dysfunction after kidney transplantation |
| Q38927090 | Primary hepatocellular carcinoma arising in a renal transplant recipient with polycystic disease |
| Q38015284 | Principles of immunosuppression. |
| Q72418120 | Priorities in transplantation research |
| Q67232430 | Proceedings of the Annual Meeting of the European Foundation for Bone Marrow Transplantation, Sils Maria (Engadine), Switzerland, April 13-16, 1980 |
| Q24632495 | Protein phosphatases and Alzheimer's disease |
| Q35146503 | Q-FISH measurement of hepatocyte telomere lengths in donor liver and graft after pediatric living-donor liver transplantation: donor age affects telomere length sustainability. |
| Q39530378 | Radionuclide evaluation of liver transplants |
| Q34289636 | Randomised trialomania? The multicentre liver transplant trials of tacrolimus |
| Q72076342 | Regulation of liver regeneration by interleukin-2 and its inhibitors: Cyclosporine A and FK 506 |
| Q39603950 | Regulation of lymphocyte growth by antagonists of interleukin-2 or its cellular receptor |
| Q41107053 | Renal and segmental pancreatic grafting with draining of exocrine secretion and initial continuous intravenous cyclosporin A in a patient with insulin-dependent diabetes and renal failure |
| Q42249528 | Renal structure and function in streptozotocin-diabetic rats treated with cyclosporin A. |
| Q41400248 | Renal transplantation in Uppsala |
| Q70256893 | Renal transplantation in children |
| Q38617129 | Renal vascular and thrombotic effects of cyclosporine |
| Q68950323 | Renography and biopsy-verified acute rejection in renal allotransplanted patients receiving cyclosporin A |
| Q87599430 | Results from a liver transplant center in northeastern Brazil that performed more than 100 transplants in 2011 |
| Q54572059 | Results of 4-year analysis of conversion from calcineurin inhibitors to mTOR inhibitors in renal transplant patients: single-center experience. |
| Q54249875 | Sandimmun(®) (ciclosporin, Cyclosporin A) Past experience and present uses in autoimmune diseases. |
| Q41872114 | Second Cadaver Kidney Transplants: Improved Graft Survival in Secondary Kidney Transplants Using Cyclosporin A |
| Q71301166 | Semi-automated high-performance liquid chromatographic method for the determination of cyclosporine in plasma and blood using column switching |
| Q51810162 | Severe gingival overgrowth associated with cyclosporine therapy. |
| Q44652391 | Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression |
| Q36179019 | Single-dose daclizumab induction therapy in patients with liver transplantation |
| Q28343921 | Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain |
| Q93379692 | Solid organ transplantation in the 21st century |
| Q39503715 | Stability of cyclosporin A in human serum |
| Q34497811 | Steps in immunosuppression for renal transplantation |
| Q74429552 | Steroid withdrawal is safe and beneficial in stable cyclosporine-treated liver transplant patients |
| Q45942079 | Steroid-Responsive Acute Rejection Should Not Be the End Point for Immunosuppressive Trials. |
| Q72420477 | Sulphinpyrazone and warfarin: a probable drug interaction |
| Q71493170 | Suppression of multiple sclerosis |
| Q41671342 | Surgical approaches for expanded organ usage in liver transplantation |
| Q44993323 | Survival and rehabilitation after orthotopic liver transplantation |
| Q68907073 | Survival from hepatic transplantation. Relationship of protein synthesis to histological abnormalities in patient selection and postoperative management |
| Q70146183 | Symptomatic cholelithiasis in pediatric renal transplant recipients |
| Q38606422 | Systemic cyclosporine and corneal transplantation |
| Q70986531 | Sézary syndrome: transformation to a high grade T-cell lymphoma after treatment with Cyclosporin A |
| Q34340969 | Tacrolimus (FK506) and the pharmaceutical/academic/regulatory gauntlet |
| Q30398451 | Targeting kinase signaling pathways with constrained peptide scaffolds |
| Q92297313 | Targeting metabolism to regulate immune responses in autoimmunity and cancer |
| Q37107203 | Techniques of orthotopic liver transplantation. |
| Q43641907 | Ten-year experience with cyclosporine as primary immunosuppression in recipients of renal allografts |
| Q34920118 | The French Heritage in Clinical Kidney Transplantation |
| Q90136673 | The Many Faces of Calcineurin Inhibitor Toxicity-What the FK? |
| Q37181790 | The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation |
| Q27015103 | The Surgical Approach to Short Bowel Syndrome - Autologous Reconstruction versus Transplantation |
| Q40113284 | The Use of Cyclosporin A Immunosuppression in Organ Grafting |
| Q42363995 | The ascension of clinical organ transplantation |
| Q50559767 | The beneficial impact of temporary porto-caval shunt in orthotopic liver transplantation: a single center analysis. |
| Q39761921 | The case for xenotransplantation |
| Q33761429 | The clinical and economic potential of cyclosporin drug interactions |
| Q34330449 | The current status of hepatic transplantation at the University of Pittsburgh |
| Q35597864 | The current status of small bowel transplantation in the UK and internationally |
| Q34330601 | The development of clinical renal transplantation |
| Q41293926 | The early days of transplantation |
| Q72753732 | The effect of cyclosporin A on peripheral blood T cell subpopulations in renal allografts |
| Q70273051 | The effect of cyclosporin A on the primary immune response to allogeneic red cells in rabbits |
| Q72471524 | The effect of long-term cyclosporin A on renal function |
| Q44791634 | The first 100 liver transplants at UCLA. |
| Q41829991 | The grafted fetal rat pancreas: features of development and rejection. |
| Q46705752 | The haemotoxicity of azathioprine in repeat dose studies in the female CD-1 mouse |
| Q91863411 | The immunoregulation of mesenchymal stem cells plays a critical role in improving the prognosis of liver transplantation |
| Q38112540 | The impact of calcineurin inhibitors on graft survival |
| Q68201149 | The incidence of gout in renal transplant recipients |
| Q34359339 | The mother lode of liver transplantation, with particular reference to our new journal |
| Q34330774 | The mystique of organ transplantation |
| Q70425853 | The occurrence of cancer in immune deficiencies |
| Q38643487 | The present state of liver transplantation and the future prospects for intestinal transplantation |
| Q51797421 | The prevention of renal impairment in patients undergoing orthotopic liver grafting by infusion of low dose dopamine. |
| Q53631739 | The relationship between proliferating cell nuclear antigen expression and histomorphometrical alterations in cyclosporin A-induced gingival overgrowth in rats. |
| Q38706410 | The risk of neoplasms in patients treated with cyclosporine A. |
| Q41553353 | The role of Epstein-Barr virus in lymphoid malignancies |
| Q53454374 | The role of endoscopic retrograde cholangiography for biliary stricture after adult living donor liver transplantation: Technical aspect and outcome |
| Q38578386 | The safety of calcineurin inhibitors for kidney-transplant patients |
| Q41450639 | The saga of liver replacement, with particular reference to the reciprocal influence of liver and kidney transplantation (1955-1967) |
| Q34346753 | The transplantation of gastrointestinal organs |
| Q30352760 | The unfinished legacy of liver transplantation: emphasis on immunology. |
| Q37305573 | The use of cyclosporin A and prednisone in cadaver kidney transplantation |
| Q57651394 | The use of cyclosporin A in clinical organ grafting |
| Q30658256 | Themes of liver transplantation |
| Q72902604 | Therapeutic Uses of Immune Suppression and Enhancement |
| Q41412514 | Therapeutic approaches for severe Epstein-Barr virus infection |
| Q70381433 | Thirty months' experience with cyclosporin in human pancreatic transplantation |
| Q40155197 | Toxicological evaluation of cyclosporin A. |
| Q36234961 | Transient immunosuppressive treatment leads to long-term retention of allogeneic myoblasts in hybrid myofibers |
| Q83393143 | Transplantation |
| Q49414396 | Transplantation Tolerance through Hematopoietic Chimerism: Progress and Challenges for Clinical Translation |
| Q34334037 | Transplantation milestones. Viewed with one- and two-way paradigms of tolerance |
| Q42843604 | Transplantation of pancreas for insulin dependent diabetes |
| Q92972903 | Transplantation versus liver resection in patients with hepatocellular carcinoma |
| Q41275725 | Transplantation: the realization of a dream |
| Q55347274 | Treatment of Sézary syndrome with cyclosporin A. |
| Q77632905 | Treatment of chronic rejection in renal transplantation by mycophenolate mofetil (MMF): a preliminary report of six-month experience |
| Q72434228 | Two cases of benign lumps after treatment with cyclosporin A |
| Q50754801 | Ultrastructural and histochemical features of the ground substance in cyclosporin A-induced gingival overgrowth. |
| Q35710903 | Use of cyclosporine in renal transplantation |
| Q79819453 | Use of cyclosporine in renal transplantation |
| Q37311411 | Variable convalescence and therapy after cadaveric renal transplantation under cyclosporin A and steroids |
| Q82888287 | Venous complications after orthotopic liver transplantation |
| Q40138083 | Viruses and cancer: Herpesviruses and tumors in the head and neck |
| Q34363663 | World's longest surviving liver-pancreas recipient |
| Q95816239 | [External comparative quality assurance in coronary surgery. Results of the 2001 German evaluation] |
| Q68592844 | [Prolonged confusion syndrome in the course of cyclosporine treatment: a state of confusion?] |
| Q71455659 | [Steroid-free treatment of renal transplant patients with cyclosporin A. A European multicentre study] |
| Q72458640 | gamma-Glutamyltranspeptidase and alcohol problems |
Search more.